Toby Michael Maher

Citée par

	Toutes	Depuis 2020
Citations	38558	27051
indice h	92	78
indice i10	289	259

7000

3500

1750

5250

2009201020112012201320142015201620172018201920202021202220232024202596 136 188 244 404 711 1149 1373 1882 2081 2721 3715 5078 5032 5847 6628 679

Accès public

Tout afficher

229 articles

18 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Athol U WellsProfessor of Respiratory Medicine, Imperial College,Adresse e-mail validée de rbht.nhs.uk
Philip L MolyneauxImperial CollegeAdresse e-mail validée de imperial.ac.uk
Vincent CottinUniversity of LyonAdresse e-mail validée de chu-lyon.fr
Michael KreuterMainz Center for pulmonary diseases, University of Mainz and Marienhaus Klinikum Mainz, GermanyAdresse e-mail validée de marienhaus.de
Andrew G NicholsonHonorary Professor of Respiratory Pathology, Imperial College, LondonAdresse e-mail validée de rbht.nhs.uk
Richard Gisli JenkinsMargaret Turner Warwick Chair of Thoracic Medicine Imperial College LondonAdresse e-mail validée de imperial.ac.uk
Martin KolbProfessor of Medicine, McMaster University HamiltonAdresse e-mail validée de mcmaster.ca
Davin Hansel 0057StudentAdresse e-mail validée de mhs.mdp.ac.id
Costabel, UlrichRuhrlandklinik, University Medicine Essen, 45239 Essen, GermanyAdresse e-mail validée de rlk.uk-essen.de
Tamera CorteUniversity of SydneyAdresse e-mail validée de sydney.edu.au
Felix ChuaRespiratory Physician, Royal Brompton HospitalAdresse e-mail validée de rbht.nhs.uk
Anne-Marie RussellProfessor College of Medicine and Dentistry University of BirminghamAdresse e-mail validée de bham.ac.uk
Moisés SelmanInstituto Nacional de Enfermedades RespiratoriasAdresse e-mail validée de iner.gob.mx
Bruno Crestaniuniversité paris diderotAdresse e-mail validée de bch.aphp.fr
Peter M GeorgeRoyal Brompton and Harefield NHS Foundation TrustAdresse e-mail validée de rbht.nhs.uk
Pauline LukeyDirector, drug discovery and developmentAdresse e-mail validée de target2treatment.com
Imre NothAdresse e-mail validée de hscmail.mcc.virginia.edu
Sujal DesaiProfessor of Practice (Thoracic Imaging), National Heart & Lung Institute, Imperial College LondonAdresse e-mail validée de rbht.nhs.uk
Adam J ByrneImperial College LondonAdresse e-mail validée de imperial.ac.uk
Shervin AssassiThe University of Texas Health Science Center at HoustonAdresse e-mail validée de uth.tmc.edu

Suivre

Toby Michael Maher

Keck Medicine of University of Southern California

Adresse e-mail validée de usc.edu - Page d'accueil

Pulmonology


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis L Richeldi, RM Du Bois, G Raghu, A Azuma, KK Brown, U Costabel, ... New England Journal of Medicine 370 (22), 2071-2082, 2014	4734	2014
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline G Raghu, M Remy-Jardin, L Richeldi, CC Thomson, Y Inoue, T Johkoh, ... American Journal of Respiratory and Critical Care Medicine 205 (9), e18-e47, 2022	1686	2022
Nintedanib for systemic sclerosis–associated interstitial lung disease O Distler, KB Highland, M Gahlemann, A Azuma, A Fischer, MD Mayes, ... New England Journal of Medicine 380 (26), 2518-2528, 2019	1500	2019
Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report HR Collard, CJ Ryerson, TJ Corte, G Jenkins, Y Kondoh, DJ Lederer, ... American journal of respiratory and critical care medicine 194 (3), 265-275, 2016	1370	2016
Interstitial lung disease in systemic sclerosis: a simple staging system NSL Goh, SR Desai, S Veeraraghavan, DM Hansell, SJ Copley, ... American journal of respiratory and critical care medicine 177 (11), 1248-1254, 2008	1322	2008
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis TE Fingerlin, E Murphy, W Zhang, AL Peljto, KK Brown, MP Steele, ... Nature genetics 45 (6), 613-620, 2013	856	2013
Pulmonary fibrosis secondary to COVID-19: a call to arms? P Spagnolo, E Balestro, S Aliberti, E Cocconcelli, D Biondini, ... The Lancet Respiratory Medicine 8 (8), 750-752, 2020	599	2020
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial TM Maher, TJ Corte, A Fischer, M Kreuter, DJ Lederer, M Molina-Molina, ... The lancet Respiratory medicine 8 (2), 147-157, 2020	591	2020
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis PL Molyneaux, MJ Cox, SAG Willis-Owen, P Mallia, KE Russell, ... American journal of respiratory and critical care medicine 190 (8), 906-913, 2014	554	2014
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised … AU Wells, KR Flaherty, KK Brown, Y Inoue, A Devaraj, L Richeldi, T Moua, ... The lancet Respiratory medicine 8 (5), 453-460, 2020	501	2020
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? TM Maher, AU Wells, GJ Laurent European Respiratory Journal 30 (5), 835-839, 2007	429	2007
Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes TL Reddy, M Tominaga, DM Hansell, J von der Thusen, D Rassl, ... European Respiratory Journal 40 (2), 377-385, 2012	401	2012
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development P Spagnolo, JA Kropski, MG Jones, JS Lee, G Rossi, T Karampitsakos, ... Pharmacology & therapeutics 222, 107798, 2021	399	2021
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury CJ Scotton, MA Krupiczojc, M Königshoff, PF Mercer, YCG Lee, ... The Journal of clinical investigation 119 (9), 2550-2563, 2009	391	2009
Global incidence and prevalence of idiopathic pulmonary fibrosis TM Maher, E Bendstrup, L Dron, J Langley, G Smith, JM Khalid, H Patel, ... Respiratory research 22, 1-10, 2021	388	2021
Short‐term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis NS Goh, RK Hoyles, CP Denton, DM Hansell, EA Renzoni, TM Maher, ... Arthritis & rheumatology 69 (8), 1670-1678, 2017	344	2017
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study RG Jenkins, JK Simpson, G Saini, JH Bentley, AM Russell, R Braybrooke, ... The lancet Respiratory medicine 3 (6), 462-472, 2015	326	2015
Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease? AJ Byrne, TM Maher, CM Lloyd Trends in molecular medicine 22 (4), 303-316, 2016	322	2016
PD-1 up-regulation on CD4⁺ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production LJ Celada, JA Kropski, JD Herazo-Maya, W Luo, A Creecy, AT Abad, ... Science translational medicine 10 (460), eaar8356, 2018	307	2018
Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study RJ Allen, J Porte, R Braybrooke, C Flores, TE Fingerlin, JM Oldham, ... The Lancet respiratory medicine 5 (11), 869-880, 2017	299	2017

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs